BioLine Financial Statements From 2010 to 2024
| BLRX Stock | ILS 8.10 0.10 1.25% |
Check BioLine RX financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BioLine RX's main balance sheet or income statement drivers, such as , as well as many indicators such as . BioLine financial statements analysis is a perfect complement when working with BioLine RX Valuation or Volatility modules.
BioLine |
BioLine RX Company Shares Outstanding Analysis
BioLine RX's Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current BioLine RX Shares Outstanding | 922.87 M |
Most of BioLine RX's fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BioLine RX is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, BioLine RX has 922.87 M of shares currently outstending. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The shares outstanding for all Israel stocks is 61.39% lower than that of the firm.
BioLine RX Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining BioLine RX's current stock value. Our valuation model uses many indicators to compare BioLine RX value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across BioLine RX competition to find correlations between indicators driving BioLine RX's intrinsic value. More Info.BioLine RX is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value BioLine RX by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for BioLine RX's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.About BioLine RX Financial Statements
BioLine RX stakeholders use historical fundamental indicators, such as BioLine RX's revenue or net income, to determine how well the company is positioned to perform in the future. Although BioLine RX investors may analyze each financial statement separately, they are all interrelated. For example, changes in BioLine RX's assets and liabilities are reflected in the revenues and expenses on BioLine RX's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in BioLine RX. Please read more on our technical analysis and fundamental analysis pages.
BioLineRx Ltd., a clinical stage biopharmaceutical development company, focuses on oncology and immunology. BioLineRx Ltd. was founded in 2003 and is based in Modiin, Israel. BIOLINE RX operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 48 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in BioLine Stock
BioLine RX financial ratios help investors to determine whether BioLine Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BioLine with respect to the benefits of owning BioLine RX security.